Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAPRWV)

• Drug Name: SaxaDapa FDC Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Diabetic complication	5A2Y	Phase 3	[1]

• Cross-matching ID:
  TTD Drug ID: DMAPRWV
  VARIDT Drug ID: DR01141

Molecule-Related Drug Atlas

Drug(s) Targeting Sodium/glucose cotransporter 2 (SLC5A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RG7201	DMJRFYB	Type-2 diabetes	5A11	Phase 3	[2]
Remogliflozin etabonate	DMW4YK1	Type-1/2 diabetes	5A10-5A11	Phase 2	[3]
Remogli ozin-etabonate	DMZFV3E	Type-2 diabetes	5A11	Phase 2	[4]
Ponalrestat	DM04ZUW	Gout	FA25	Discontinued in Phase 3	[5]

Drug(s) Targeting Dipeptidyl peptidase 4 (DPP-4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Saxagliptin	DMGXENV	Type-2 diabetes	5A11	Approved	[6]
Sitagliptin	DMGDKXN	Cystic fibrosis	CA25	Approved	[7]
Alogliptin	DM8WI3R	Type-2 diabetes	5A11	Approved	[8]
Linagliptin	DMWFJTR	Non-insulin dependent diabetes	5A11	Approved	[9]
Vildagliptin	DMYN59P	Type-2 diabetes	5A11	Approved	[10]
Dapagliflozin Propanediol; Saxagliptin Hydrochloride	DM34TXO	Type-2 diabetes	5A11	Approved	[11]
Anagliptin	DMJXIC9	Type-2 diabetes	5A11	Approved	[12]
LC-150444	DM09RKB	Type-2 diabetes	5A11	Phase 3	[13]
Dutogliptin	DMM5VTA	Type-2 diabetes	5A11	Phase 3	[14]
MK-3102	DM3PSUF	Type-2 diabetes	5A11	Phase 3	[15]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dipeptidyl peptidase 4 (DPP-4)	TTDIGC1	DPP4_HUMAN	Modulator	[1]
Sodium/glucose cotransporter 2 (SLC5A4)	TTN7Y4P	SC5A4_HUMAN	Modulator	[1]

References

• [1] Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7.
• [2] Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014 Mar 28;13:65.
• [3] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [4] Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. BMC Pharmacol Toxicol.2013 Apr 30;14:25.
• [5] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).
• [6] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [7] Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther. 2009 Oct;124(1):113-38.
• [8] Clinical pipeline report, company report or official report of Takeda (2009).
• [9] Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
• [10] Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87.
• [11] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [12] Diabetes Treatment. Diabetes Care. 2009 March; 32(3): e25-e30.
• [13] Clinical pipeline report, company report or official report of ShangHai APIs Chemical.
• [14] Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes Metab. 2010 Apr;12(4):348-55.
• [15] Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. J Med Chem. 2014 Apr 24;57(8):3205-12.